Recent News

• 02.10.2026 - Neuronetics Announces Selected Preliminary Unaudited Fourth Quarter and Full Year 2025 Financial Results
• 11.12.2025 - TRICARE West Expands NeuroStar® TMS Coverage to Include Adolescents Aged 15+ Struggling with Depression
• 11.04.2025 - Neuronetics Reports Third Quarter 2025 Financial and Operating Results and Announces CEO Transition Plan
• 10.31.2025 - Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
• 10.30.2025 - Neuronetics Announces Three-Year Exclusive Partnership with Elite DNA Behavioral Health to Expand NeuroStar Access and Operational Excellence
• 10.21.2025 - Neuronetics to Report Third Quarter 2025 Financial and Operating Results and Host Conference Call
• 09.17.2025 - New York State Medicaid Expands Coverage for TMS Therapy, Including NeuroStar® Advanced Therapy, to Treat Major Depressive Disorder (MDD)

Recent Filings

• 02.04.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 01.22.2026 - 8-K Current report
• 01.06.2026 - 8-K Current report
• 12.31.2025 - 4 Statement of changes in beneficial ownership of securities
• 12.31.2025 - 4 Statement of changes in beneficial ownership of securities
• 11.24.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 11.04.2025 - 8-K Current report
• 11.04.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 11.04.2025 - EX-99.1 EX-99.1
• 10.22.2025 - 4 Statement of changes in beneficial ownership of securities